Table 1.
Characteristics of HCT Survivors and Sibling Controls
| Variable | Survivors (n = 151)
|
Controls (n = 92)
|
||
|---|---|---|---|---|
| Category | n (%) | Mean +/− SE | n (%) | Mean +/− SE |
| Age at study, yr | 24 +/− 0.6 | 24.2 +/− 0.7 | ||
| Sex | ||||
| Male | 87 (57.6) | 49 (53.6) | ||
| Female | 64 (42.4) | 43 (46.4) | ||
| Race/Ethnicity | ||||
| White non-Hispanic | 137 (90.7) | 85 (92.4) | ||
| Other | 14 (9.3) | 7 (7.6) | ||
| Tanner stage | ||||
| 1 | 6 (4.3) | 2 (2.3) | ||
| 2 | 4 (2.8) | 3 (3.5) | ||
| 3 | 10 (7.1) | 1 (1.2) | ||
| 4 | 9 (6.4) | 9 (10.5) | ||
| 5 | 112 (79.4) | 71 (82.6) | ||
| Diagnosis | ||||
| ALL | 47 (31.1) | NA | ||
| AML | 54 (35.7) | |||
| CML | 15 (9.9) | |||
| HOD | 12 (8.0) | |||
| MDS | 13 (8.6) | |||
| Others | 10 (6.6) | |||
| Age at most recent HCT, yr | 11.2 +/− 0.5 | NA | ||
| HCT Preparative Regimen | ||||
| TBI + CNS Radiation | 31 (20.5) | NA | ||
| TBI without CNS Radiation | 85 (56.3) | |||
| Chemotherapy without TBI* | 35 (23.2) | |||
| HCT Type | ||||
| Allogeneic | 116 (76.8) | NA | ||
| Autologous | 35 (23.2) | |||
| GVHD** | 76 (65.5) | NA | ||
(ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CNS, Central Nervous System; HOD, Hodgkin’s lymphoma; MDS, myelodysplastic syndrome; NA, not applicable; GVHD, Graft versus host disease; TBI, total body irradiation)
*
Some survivors received other radiation before or after HCT: mantle/mediastinal (n = 10 for HD), arm, orbit (n = 2 for chloromas), temple (n = 1 with history of sarcoma and HCT for secondary AML), abdominal (n = 1 for non-Hodgkin lymphoma).
**
Among the 116 allogeneic HSCT survivors